Arterial stiffness and multiple organ damage: a longitudinal study in population
Related Experiment Video
Updated: Jan 22, 2026

Measuring the Carotid to Femoral Pulse Wave Velocity Cf-PWV to Evaluate Arterial Stiffness
Published on: May 3, 2018
Angelo Scuteri1, Cristopher H Morrell2,3, Danilo Alunni Fegatelli4
1Department of Medical, Surgical, and Experimental Sciences, University of Sassari, Sassari, Italy. ascuteri@uniss.it.
Aims:
Previous cross-sectional observation identified arterial aging, indexed as pulse-wave velocity (PWV), as a key determinant of the simultaneous multiple organ damage (heart, carotid artery, and kidney). The aim of the present cohort study is to investigate trajectories of repeated measures of PWV and traditional CV risk factors in subjects who eventually presented clinical evidence of multiple organ damage in the SardiNIA study.
Methods And Results:
Organ damage was measured in the heart (left ventricular hypertrophy, LVH), the common carotid artery (intima-media thickness > 0.9 mm and/or plaque), and the kidney (eGFR < 60 ml/min/1.73 m2) of 2130 men and women of a broad age range participating the SardiNIA study. SHATS was defined as the simultaneous occurrence of all the three-organ damages. Trajectory in traditional CV risk factors and PWV was analyzed retrospectively (four observations over 9 years) according to the number of organ damage (from 0 to 3). Compared to subjects with no organ damage, after controlling for traditional CV risk factors, each 1 m/s increase in baseline PWV was accompanied by a 93% higher odds of developing SHATS; and each 1 cm/s (0.01 m/s) annual increase in PWV by a 31% greater odds of developing SHATS.
Conclusions:
Arterial stiffness, a proxy of arterial aging that can be measured clinically as PWV, is an integrated predictive marker of multiple age-associated organ damage recognized as clinical diseases.
Related Concept Videos
Longitudinal Studies
Longitudinal Research
Multiple Allele Traits
What are Populations and Communities?
What is Population Genetics?
Bioavailability Study Design: Single Versus Multiple Dose Studies

